Streetwise Biotechnology / Pharmaceuticals Articles


Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'

Research Report
  ()
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. read more >
News Update

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment

News Update
  ()
With this achievement, the firm expands its potential partnering opportunities. read more >

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs

Contributed Opinion
  ()
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. read more >

Catasys…Future's So Bright

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. read more >

Biotech to Expand Precision Medicine Services via New Partnership

Research Report
  ()
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. read more >

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View

Contributed Opinion
  ()
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. read more >

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant

Research Report
  ()
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. read more >

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder

Research Report
  ()
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. read more >

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner

  ()
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. read more >
News Update

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership

News Update
  ()
This "patient-care solution" is designed to help retailers make product recommendations. read more >
News Update

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease

News Update
  ()
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. read more >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential

Research Report
  ()
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. read more >

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'

Research Report
  ()
A LifeSci Capital report presented a handful of key points about the firm. read more >

Texas Heart Takes to the CoreoGraft

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. read more >
News Update

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements

News Update
  ()
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. read more >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters

Research Report
  ()
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. read more >

DURECT Receives Return on Schizophrenia Drug Approval

  ()
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. read more >
News Update

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm

News Update
  ()
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. read more >

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

Research Report
  ()
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. read more >

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal

Research Report
  ()
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. read more >
News Update

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock

News Update
  ()
This is the second large shipment to the Philippine distributor. read more >

This Company Has Better Numbers than Tilray at 1/25th the Price

Contributed Opinion
  ()
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. read more >

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'

Research Report
  ()
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. read more >

Cancer Vaccine Developer Expands Its Collaboration with Merck

Research Report
  ()
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. read more >
Management Q&A: View from the Top

Medical Use of Nitric Oxide Expands as Costs Come Down

Managment Q&A: View from the Top
  ()
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. read more >
Showing Results: 26 to 50 of 69 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts